Selank Anxiolytic and Cognitive Research: Published Studies Reviewed
A factual review of peer-reviewed studies on Selank, a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin, investigated for anxiolytic effects, cognitive function, and neurochemical modulation.
Selank: Overview
Selank (TKPRPGP) is a synthetic heptapeptide based on tuftsin (TKPR), a naturally occurring peptide fragment of immunoglobulin G with known immunomodulatory and neuroactive properties. Selank extends the tuftsin tetrapeptide with a C-terminal Pro-Gly-Pro sequence โ the same stabilizing addition used in Semax โ to improve metabolic stability against tissue peptidases. Developed at the Institute of Molecular Genetics in Russia, Selank has been investigated primarily in the context of anxiety, stress response, cognitive enhancement, and GABA system modulation. It is registered as a drug in Russia and Ukraine under the brand name Selank. The following review covers key published research findings without therapeutic claims.
Study 1: Anxiolytic Properties in Animal Stress Models
Multiple preclinical studies have examined Selank in validated rodent anxiety models including the elevated plus maze (EPM), open field test (OFT), and conflict test paradigms.
Anxiolytic effects observed in stress models included:
- Increased open arm exploration in elevated plus maze without sedation
- Reduced immobility in forced swim test โ associated with stress-coping behavior
- No significant motor impairment at anxiolytic doses (by contrast with benzodiazepines)
- Reduced stress-induced increases in plasma corticosterone in some models
- Effects persisted for 24โ48 hours post-single-dose administration in some protocols
Study 2: GABA System Interactions
Grigoriev et al. and related research have investigated Selank's interactions with the GABAergic system โ the primary inhibitory neurotransmitter system and the target of classical benzodiazepine anxiolytics.
Findings regarding GABAergic mechanisms:
- Allosteric potentiation of GABA-A receptor current in patch-clamp preparations
- Benzodiazepine receptor site interaction demonstrated by competitive binding studies
- Effect partially blocked by flumazenil (benzodiazepine antagonist) in some models
- Weaker intrinsic efficacy than classical benzodiazepines โ characteristic of partial allosteric modulation
- No significant muscle relaxation or anticonvulsant effects at anxiolytic doses (unlike full BZD agonists)
The partial/selective GABA-A modulation profile distinguishes Selank from traditional benzodiazepines in preclinical models. Whether this translates to meaningfully different therapeutic profiles in humans requires clinical validation.
Cognitive Function Studies in Rodent Models
Beyond anxiolytic effects, Selank has been examined in learning and memory paradigms, often in models where stress or anxiety impairs cognitive performance.
Findings in cognitive and learning models:
- Improved passive avoidance retention scores in multiple rodent cohorts
- Enhanced working memory in radial arm maze under mild stress conditions
- Normalization of stress-induced memory impairment (stress as a confounding factor in many models)
- Increased BDNF expression observed in some hippocampal studies (similar to Semax profile)
- Improved learning in aged rat models โ relevant to aging-associated cognitive decline research
Immunomodulatory Properties from Tuftsin Ancestry
Tuftsin, Selank's parent peptide, has established immunostimulatory properties โ it is a natural activator of phagocytic activity in macrophages and neutrophils. Selank inherits some of these properties.
Immunological findings included:
- Increased phagocytic activity in peritoneal macrophage cultures
- Modulation of IL-6 and TNF-ฮฑ production in activated immune cells
- Potential bidirectional immunomodulation: stimulates innate immunity while potentially attenuating excessive inflammatory response
- The neuro-immune interface โ where Selank's CNS and immune effects may interact โ is an active area of research interest
Molecular Profile
| Property | Value |
|---|---|
| Full name | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) |
| Parent sequence | Tuftsin (TKPR) + Pro-Gly-Pro C-terminal extension |
| Molecular weight | ~751 Da |
| Primary research contexts | Anxiolytic effects, GABA modulation, cognitive function, immunomodulation |
| Regulatory status | Registered pharmaceutical in Russia and Ukraine (brand: Selank) |
| Storage | Lyophilized: -20ยฐC; Reconstituted: 2โ8ยฐC, use within 30 days |
Quick Reference Summary
- Origin: Synthetic heptapeptide based on tuftsin with C-terminal metabolic stabilization
- Anxiolytic research: EPM performance comparable to diazepam without sedation or motor impairment
- Mechanism: GABA-A positive allosteric modulation at benzodiazepine sites โ partial modulator profile
- Cognitive research: Improved passive avoidance and working memory, partially via stress-reduction
- Immunomodulation: Retains tuftsin-derived macrophage-activating properties
- Use context: Research-grade compound for in vitro and preclinical laboratory use only